Cargando…
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have transformed the treatment landscape in front-line and recurrent high-grade serous ovarian cancer. Maintenance strategies with PARPi have been assessed in randomized phase III trials in ovarian cancer; switch maintenance in the case of olapa...
Autores principales: | Madariaga, Ainhoa, Bowering, Valerie, Ahrari, Soha, Oza, Amit M, Lheureux, Stephanie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398227/ https://www.ncbi.nlm.nih.gov/pubmed/32276934 http://dx.doi.org/10.1136/ijgc-2020-001288 |
Ejemplares similares
-
Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis
por: Stemmer, Amos, et al.
Publicado: (2020) -
RNA regulation by Poly(ADP-ribose) polymerases
por: Bock, Florian J., et al.
Publicado: (2015) -
Mitotic functions of poly(ADP-ribose) polymerases
por: Slade, Dea
Publicado: (2019) -
The Antiviral Activities of Poly-ADP-Ribose Polymerases
por: Malgras, Mathilde, et al.
Publicado: (2021) -
Impact of Age on Poly(ADP-Ribose) Polymerase Inhibitor (PARPi)-Induced Lymphopenia: A Scoping Review of the Literature and Internal Analysis of a Retrospective Database
por: Antherieu, Gabriel, et al.
Publicado: (2023)